Production

ImpediMed (ASX:IPD) publishes article on lymphedema risk factors – The Market Herald

Subscribe

Be the first with news that moves the market

  • ImpediMed (IPD) publishes an article on risk factors for breast cancer-related lymphedema
  • Key findings of the article include support for the use of a prospective care monitoring model and identify patients who could benefit from more frequent follow-up appointments
  • The results should both inform clinical practice and patient education, and potentially alleviate some of the distress about air travel frequently expressed by breast cancer survivors.
  • ImpediMed last traded in the gray at 5.8 cents per share at 2:05 p.m. AEST

ImpediMed (IPD) has published an article on risk factors for breast cancer-related lymphedema.

The article was published in an international journal of the American Cancer Society called “Cancer”, which publishes high-impact, peer-reviewed original articles.

Key findings from the article included support for the use of a prospective care monitoring model and identified patients who could benefit from more frequent follow-up appointments.

The article supported previous studies that identified patients at higher risk, included patients receiving axillary lymph node dissection (ALND), taxane-based chemotherapy, or those with a body mass index greater than 30.

Additionally, the authors found that living in a rural area increased the risk, while air travel did not increase the risk.

The journal also commissioned an editorial which was published together with the manuscript.

The editorial commented that the work “contributes greatly to the body of BCRL literature as it describes individual patient risk factors for the development of BCRL in an international prospective cohort.”

Principal investigator Sheila H. Ridner said the study represents the most comprehensive prospective examination of breast cancer-related lymphedema risk factors to date.

“The findings will not only inform clinical practice and patient education, but may also alleviate some of the distress about air travel frequently expressed by breast cancer survivors,” said Sheila Ridner.

ImpediMed last traded in the gray at 5.8 cents at 2:05 p.m. AEST.